Angina Pectoris – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Angina Pectoris is chest pain or discomfort resulting from atherosclerotic heart disease. It is a symptom of coronary artery disease (CAD) that occurs when the heart muscle doesn't get as much blood as needed, usually because one or more arteries are narrowed or blocked. People experiencing angina feel uncomfortable pressure, fullness, squeezing, or pain in the center of the chest. It is rarely sharply localized and is typically not spasmodic. The distribution of the discomfort may vary widely in different patients, but it does not usually differ from episode to episode for a single patient. It can be stable or unstable. Stable angina describes predictable chest pain caused by exertion or mental or emotional stress, occurring consistently for a month or more. Unstable angina is a chest pain of coronary origin arising in response to progressively less exercise or fewer other stimuli than ordinarily required to produce angina or angina that is a change in pattern from stable angina. The prevalence of Angina Pectoris in the USA varies from 4.5 MN to 5.2 MN among more than 40 years population.

The competitive landscape of Angina Pectoris includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Angina Pectoris across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Angina Pectoris Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Angina Pectoris – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          T89 capsule      Tasly Pharmaceuticals, Inc.       Phase 3

2          RANCAD          TSH Biopharm Corporation Limited        Phase 3

3          Cilostazol          Korea Otsuka Pharmaceutical Co., Ltd.  Phase 3

4          IMB-1018972    Imbria Pharmaceuticals, Inc.      Phase 2

5          Ad5FGF-4         Angionetics Inc. Phase 3

6          Erenumab         Amgen  Phase 2

7          Ranolazine        Gilead Sciences            Phase 2

8          telcagepant       Merck Sharp & Dohme Corp.     Phase 1

9          CLBS16            Caladrius Biosciences, Inc.        Phase 2

10        Eptifibatide (Integrilin)    Organon and Co            Phase 3

Continued